BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie Y, Wang Y, Li J, Hang Y, Jaramillo L, Wehrkamp CJ, Phillippi MA, Mohr AM, Chen Y, Talmon GA, Mott JL, Oupický D. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. Theranostics 2018;8:4305-20. [PMID: 30214622 DOI: 10.7150/thno.26506] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Meadows V, Francis H. MicroRNAs and cholangiocarcinoma: elucidating the effects of tiny giants. AME Med J 2018;3:98. [PMID: 30506034 DOI: 10.21037/amj.2018.09.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Meng F, Kwon S, Wang J, Yeo Y. Immunoactive drug carriers in cancer therapy. Biomaterials for Cancer Therapeutics. Elsevier; 2020. pp. 53-94. [DOI: 10.1016/b978-0-08-102983-1.00003-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Wu HJ, Chu PY. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. Int J Mol Sci 2019;20:E4154. [PMID: 31450710 DOI: 10.3390/ijms20174154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
4 Zuo J, Zhang Z, Li M, Yang Y, Zheng B, Wang P, Huang C, Zhou S. The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role. Mol Cancer 2022;21:30. [PMID: 35081965 DOI: 10.1186/s12943-021-01488-3] [Reference Citation Analysis]
5 Jin D, Guo J, Wu Y, Du J, Wang X, An J, Hu B, Kong L, Di W, Wang W. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC. Theranostics 2019;9:2036-55. [DOI: 10.7150/thno.32738] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
6 Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 2021;13:1113-34. [PMID: 34190581 DOI: 10.2217/imt-2021-0126] [Reference Citation Analysis]
7 Sato K, Glaser S, Alvaro D, Meng F, Francis H, Alpini G. Cholangiocarcinoma: novel therapeutic targets. Expert Opin Ther Targets. 2020;24:345-357. [PMID: 32077341 DOI: 10.1080/14728222.2020.1733528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Xia W, Tao Z, Zhu B, Zhang W, Liu C, Chen S, Song M. Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy. Int J Mol Sci 2021;22:9118. [PMID: 34502028 DOI: 10.3390/ijms22179118] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhang L, Peng H, Zhang W, Li Y, Liu L, Leng T. Yeast Cell wall Particle mediated Nanotube-RNA delivery system loaded with miR365 Antagomir for Post-traumatic Osteoarthritis Therapy via Oral Route. Theranostics 2020;10:8479-93. [PMID: 32754258 DOI: 10.7150/thno.46761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
10 Huang WK, Yeh CN. The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma. Biomolecules. 2020;10. [PMID: 33007962 DOI: 10.3390/biom10101396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Chang W, Wang Y, Li W, Shi L, Geng Z. MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting Cyclin D1. J Cell Mol Med. 2019;23:4945-4954. [PMID: 31199052 DOI: 10.1111/jcmm.14312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
12 Wang Y, Xie Y, Kilchrist KV, Li J, Duvall CL, Oupický D. Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy. ACS Appl Mater Interfaces 2020;12:4308-22. [PMID: 31939276 DOI: 10.1021/acsami.9b21214] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 20.0] [Reference Citation Analysis]
13 Hu X, Chen Q, Guo H, Li K, Fu B, Chen Y, Zhao H, Wei M, Li Y, Wu H. Identification of Target PTEN-Based miR-425 and miR-576 as Potential Diagnostic and Immunotherapeutic Biomarkers of Colorectal Cancer With Liver Metastasis. Front Oncol 2021;11:657984. [PMID: 34490081 DOI: 10.3389/fonc.2021.657984] [Reference Citation Analysis]
14 Ding L, Tang S, Tang W, Mosley DD, Yu A, Sil D, Romanova S, Bailey KL, Knoell DL, Wyatt TA, Oupický D. Perfluorocarbon Nanoemulsions Enhance Therapeutic siRNA Delivery in the Treatment of Pulmonary Fibrosis. Adv Sci (Weinh) 2022;9:e2103676. [PMID: 34994102 DOI: 10.1002/advs.202103676] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Barbato A, Piscopo F, Salati M, Reggiani-bonetti L, Franco B, Carotenuto P. Micro-RNA in Cholangiocarcinoma: Implications for Diagnosis, Prognosis, and Therapy. JMP 2022;3:88-103. [DOI: 10.3390/jmp3020009] [Reference Citation Analysis]
16 Ma L, Xie X, Liu H, Huang Y, Wu H, Jiang M, Xu P, Ye X, Zhou C. Potent antibacterial activity of MSI-1 derived from the magainin 2 peptide against drug-resistant bacteria. Theranostics 2020;10:1373-90. [PMID: 31938070 DOI: 10.7150/thno.39157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
17 Wang Y, Xie Y, Williams J, Hang Y, Richter L, Becker M, Amador C, Oupický D, Hyde RK. Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia. Cancer Gene Ther 2020;27:45-55. [PMID: 31028289 DOI: 10.1038/s41417-019-0095-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
18 Wang D, Xiong F, Wu G, Liu W, Wang B, Chen Y. MiR-155-5p suppresses SOX1 to promote proliferation of cholangiocarcinoma via RAF/MEK/ERK pathway. Cancer Cell Int 2021;21:656. [PMID: 34876142 DOI: 10.1186/s12935-021-02374-0] [Reference Citation Analysis]
19 Zhang C, Hang Y, Tang W, Sil D, Jensen-smith HC, Bennett RG, Mcvicker BL, Oupický D. Dually Active Polycation/miRNA Nanoparticles for the Treatment of Fibrosis in Alcohol-Associated Liver Disease. Pharmaceutics 2022;14:669. [DOI: 10.3390/pharmaceutics14030669] [Reference Citation Analysis]
20 Xie Y, Hang Y, Wang Y, Sleightholm R, Prajapati DR, Bader J, Yu A, Tang W, Jaramillo L, Li J, Singh RK, Oupický D. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy. ACS Nano 2020;14:255-71. [PMID: 31927946 DOI: 10.1021/acsnano.9b03978] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 25.5] [Reference Citation Analysis]